ALNYLAM PHARMACEUTICALS, INC. Selling, General and Administrative Expense
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Selling, General and Administrative Expense of $347.92 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $347.92M, a 7.61% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $325.37M, a 10.17% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $322.08M, a 45.74% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2025-06-30 was $323.31M, a 30.16% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2025 was $1.21B, a 24.11% increase from fiscal 2024.
- ALNYLAM PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2024 was $975.53M, a 22.61% increase from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2023 was $795.65M, a 3.24% increase from fiscal 2022.
- ALNYLAM PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2022 was $770.66M, a 24.17% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $347.92M 10-Q · filed 2026-07-30 | $670.47M 10-Q · filed 2026-07-30 | ||
| 2025-12-31 | $325.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $647.45M derived: sum of 2 quarters · filed 2026-02-12 | $970.76M derived: sum of 3 quarters · filed 2026-07-30 | $1.21B 10-K · filed 2026-02-12 |
| 2025-09-30 | $322.08M 10-Q · filed 2025-10-30 | $645.39M derived: sum of 2 quarters · filed 2026-07-30 | $885.34M 10-Q · filed 2025-10-30 | $1.18B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $323.31M 10-Q · filed 2026-07-30 | $563.26M 10-Q · filed 2026-07-30 | $858.60M derived: sum of 3 quarters · filed 2026-07-30 | $1.08B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $239.95M 10-Q · filed 2025-05-01 | $535.29M derived: sum of 2 quarters · filed 2026-02-12 | $756.28M derived: sum of 3 quarters · filed 2026-02-12 | $1.00B derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-12-31 | $295.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $516.33M derived: sum of 2 quarters · filed 2026-02-12 | $764.73M derived: sum of 3 quarters · filed 2026-02-12 | $975.53M 10-K · filed 2026-02-12 |
| 2024-09-30 | $220.99M 10-Q · filed 2025-10-30 | $469.39M derived: sum of 2 quarters · filed 2025-10-30 | $680.19M 10-Q · filed 2025-10-30 | $878.31M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | $248.40M 10-Q · filed 2025-07-31 | $459.19M 10-Q · filed 2025-07-31 | $657.32M derived: sum of 3 quarters · filed 2026-02-12 | $856.49M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | $210.80M 10-Q · filed 2025-05-01 | $408.92M derived: sum of 2 quarters · filed 2026-02-12 | $608.10M derived: sum of 3 quarters · filed 2026-02-12 | $822.78M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | $198.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $397.30M derived: sum of 2 quarters · filed 2026-02-12 | $611.99M derived: sum of 3 quarters · filed 2026-02-12 | $795.65M 10-K · filed 2026-02-12 |
| 2023-09-30 | $199.18M 10-Q · filed 2024-10-31 | $413.86M derived: sum of 2 quarters · filed 2024-10-31 | $597.52M 10-Q · filed 2024-10-31 | $807.87M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-06-30 | $214.69M 10-Q · filed 2024-08-01 | $398.35M 10-Q · filed 2024-08-01 | $608.69M derived: sum of 3 quarters · filed 2025-02-13 | $844.55M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-03-31 | $183.66M 10-Q · filed 2024-05-02 | $394.00M derived: sum of 2 quarters · filed 2025-02-13 | $629.86M derived: sum of 3 quarters · filed 2025-02-13 | $799.85M derived: sum of 4 quarters · filed 2025-02-13 |
| 2022-12-31 | $210.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $446.20M derived: sum of 2 quarters · filed 2025-02-13 | $616.19M derived: sum of 3 quarters · filed 2025-02-13 | $770.66M 10-K · filed 2025-02-13 |
| 2022-09-30 | $235.86M 10-Q · filed 2023-11-02 | $405.84M derived: sum of 2 quarters · filed 2023-11-02 | $560.31M 10-Q · filed 2023-11-02 | $746.70M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $169.98M 10-Q · filed 2023-08-03 | $324.45M 10-Q · filed 2023-08-03 | $510.84M derived: sum of 3 quarters · filed 2024-02-15 | $652.91M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $154.47M 10-Q · filed 2023-05-04 | $340.85M derived: sum of 2 quarters · filed 2024-02-15 | $482.93M derived: sum of 3 quarters · filed 2024-02-15 | $628.25M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $186.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $328.46M derived: sum of 2 quarters · filed 2024-02-15 | $473.78M derived: sum of 3 quarters · filed 2024-02-15 | $620.64M 10-K · filed 2024-02-15 |
| 2021-09-30 | $142.07M 10-Q · filed 2022-10-27 | $287.40M derived: sum of 2 quarters · filed 2022-10-27 | $434.26M 10-Q · filed 2022-10-27 | $600.55M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $145.32M 10-Q · filed 2022-07-28 | $292.18M 10-Q · filed 2022-07-28 | $458.47M derived: sum of 3 quarters · filed 2023-02-23 | $625.95M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $146.86M 10-Q · filed 2022-04-28 | $313.15M derived: sum of 2 quarters · filed 2023-02-23 | $480.62M derived: sum of 3 quarters · filed 2023-02-23 | $608.52M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $166.29M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $333.76M derived: sum of 2 quarters · filed 2023-02-23 | $461.66M derived: sum of 3 quarters · filed 2023-02-23 | $588.42M 10-K · filed 2023-02-23 |
| 2020-09-30 | $167.47M 10-Q · filed 2021-10-28 | $295.37M derived: sum of 2 quarters · filed 2021-10-28 | $422.13M 10-Q · filed 2021-10-28 | $578.41M derived: sum of 4 quarters · filed 2022-02-10 |
| 2020-06-30 | $127.90M 10-Q · filed 2021-08-03 | $254.66M 10-Q · filed 2021-08-03 | $410.93M derived: sum of 3 quarters · filed 2022-02-10 | $531.28M derived: sum of 4 quarters · filed 2022-02-10 |
| 2020-03-31 | $126.76M 10-Q · filed 2021-04-29 | $283.04M derived: sum of 2 quarters · filed 2022-02-10 | $403.39M derived: sum of 3 quarters · filed 2022-02-10 | $516.16M derived: sum of 4 quarters · filed 2022-02-10 |
| 2019-12-31 | $156.28M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | $276.63M derived: sum of 2 quarters · filed 2022-02-10 | $389.40M derived: sum of 3 quarters · filed 2022-02-10 | $479.00M 10-K · filed 2022-02-10 |
| 2019-09-30 | $120.35M 10-Q · filed 2020-11-05 | $233.12M derived: sum of 2 quarters · filed 2020-11-05 | $322.73M 10-Q · filed 2020-11-05 | $431.42M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-06-30 | $112.77M 10-Q · filed 2020-08-06 | $202.38M 10-Q · filed 2020-08-06 | $311.06M derived: sum of 3 quarters · filed 2021-02-11 | $427.61M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-03-31 | $89.61M 10-Q · filed 2020-05-06 | $198.30M derived: sum of 2 quarters · filed 2021-02-11 | $314.84M derived: sum of 3 quarters · filed 2021-02-11 | $399.52M derived: sum of 4 quarters · filed 2021-02-11 |
| 2018-12-31 | $108.69M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $225.23M derived: sum of 2 quarters · filed 2021-02-11 | $309.91M derived: sum of 3 quarters · filed 2021-02-11 | $382.36M 10-K · filed 2021-02-11 |
| 2018-09-30 | $116.55M 10-Q · filed 2019-10-31 | $201.22M derived: sum of 2 quarters · filed 2019-10-31 | $273.67M 10-Q · filed 2019-10-31 | $341.13M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-06-30 | $84.68M 10-Q · filed 2019-08-06 | $157.13M 10-Q · filed 2019-08-06 | $224.58M derived: sum of 3 quarters · filed 2020-02-13 | $272.23M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-03-31 | $72.45M 10-Q · filed 2019-05-02 | $139.90M derived: sum of 2 quarters · filed 2020-02-13 | $187.55M derived: sum of 3 quarters · filed 2020-02-13 | |
| 2017-12-31 | $67.45M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $115.10M derived: sum of 2 quarters · filed 2020-02-13 | $199.37M 10-K · filed 2020-02-13 | |
| 2017-09-30 | $47.64M 10-Q · filed 2018-11-07 | $131.91M 10-Q · filed 2018-11-07 | ||
| 2016-12-31 | $89.35M 10-K · filed 2019-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |